Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)
Clinical trial NCT03293498 · COMPLETED
Trial details
- NCT number
- NCT03293498
- Sponsor
- Novavax
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-09-18
- Primary completion
- 2018-03-14
- Enrollment
- 330
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.